#Measles resurgence in #Italy: analysis of temporal patterns of viral transmission, #surveillance #performance, and #vaccination coverage at national and regional levels, October 2023 to March 2025

 

Abstract

BACKGROUND

Following substantial progress towards measles elimination after the COVID-19 pandemic, Italy experienced a marked increase in measles cases in 2024.

AIM

Our aim was to describe measles epidemiology in Italy, October 2023–March 2025, and assess vaccination coverage, surveillance performance at national and regional levels, and temporal patterns of transmission.

METHODS

Numbers of measles cases and outbreaks were reviewed. Vaccination coverage and surveillance indicators were described at national and regional levels. Measles variants were classified by genotype and Distinct Sequence Identifier (DSId). Temporal transmission patterns of measles variants were assessed nationally and regionally to identify sustained transmission chains (≥ 12 consecutive months).

RESULTS

In total, 1,311 measles cases were reported, with 178 outbreaks. Cases’ median age was 30.9 years (IQR: 15.6–39.8); 601 were female (45.8%) and 710 male (54.2%). Only 3.1% (38/1,230) were fully vaccinated. In 2024, the first-dose vaccination coverage increased to 94.77% (95% CI: 94.70–94.84%) nationally, while second-dose coverage declined to 84.45% (95% CI: 84.35–84.55%). Among all cases, 12.1% (n = 158) were imported/importation-related, 64.1% (n = 841) were of unknown origin and 52.8% had DSId data available (n = 692), with high regional heterogeneity. Twenty-five measles variants were identified. One variant (D8–5963) showed sustained national transmission for over 12 months, meeting criteria for re-established endemic transmission, although no single region showed uninterrupted ≥ 12-month circulation.

CONCLUSION

Measles resurgence in Italy was marked by persistent immunity gaps, heterogeneous surveillance performance, and sustained national circulation of a D8 variant, indicating loss of near-elimination status. Strengthening vaccination strategies and enhancing molecular surveillance is urgently needed to restore progress towards measles elimination.

Source: Eurosurveillance Journal, https://doi.org/10.2807/1560-7917.ES.2026.31.45.2600090

____

Detection of #Shamonda virus in field-collected #Culicoides (Diptera: Ceratopogonidae), #Switzerland, August to September 2026

 

Abstract

In August–September 2026, we detected Shamonda virus (SHAV) (genus Orthobunyavirus) RNA in 15 of 34 pools of 610 field-collected Culicoides biting midges (Diptera: Ceratopogonidae) of C. obsoletus group, C. circumscriptus and C. festivipennis on cattle farms in Switzerland. The overall minimum infection rate was 24.59 per 1,000 females tested. Further investigations of the role of local biting midge species in virus transmission and the potential implications for animal and human health are needed, considering possible zoonotic concerns.

Source: Eurosurveillance Journal, https://doi.org/10.2807/1560-7917.ES.2026.31.45.2600927

____

#Baloxavir and #molnupiravir protect against severe #influenza #H5N1 #infection in immunosuppressed hamsters

 

Abstract

Highly pathogenic avian influenza A(H5N1) viruses continue to expand their geographic and host range, raising concerns about zoonotic transmission and pandemic preparedness. Immunocompromised individuals often develop severe and prolonged disease, yet evidence guiding antiviral therapy remains limited. Here, we characterized the pathogenesis and assessed direct-contact transmission of an influenza A(H5N1) clade 2.3.4.4b genotype D1.1 virus recently isolated from a human case in British Columbia, Canada, in cyclophosphamide-immunosuppressed hamsters, with normal hamsters included for comparison of infection outcomes and viral shedding kinetics. We also evaluated the antiviral efficacy of oseltamivir (20 mg/kg twice daily for 5 days), baloxavir (50 mg/kg, 2 doses), and molnupiravir (50 or 200 mg/kg twice daily) as monotherapies or in combination (oseltamivir with low-dose molnupiravir) in immunosuppressed hamsters. While normal hamsters showed no mortality and achieved viral clearance, infection in immunosuppressed hamsters caused severe disease characterized by prolonged viral replication, neuroinvasion, and 75% mortality, with no direct-contact transmission detected. In the antiviral efficacy experiment, placebo-treated hamsters exhibited 50% mortality. Baloxavir resulted in 100% survival, shortened viral shedding, reduced viral replication and pulmonary inflammatory responses, and prevented neuroinvasion. High-dose molnupiravir also prevented mortality and achieved viral clearance in lung and brain tissues. Combination therapy resulted in 75% survival and similarly achieved viral clearance in both tissues, with reduced morbidity compared with oseltamivir and low-dose molnupiravir monotherapies. Oseltamivir resulted in 75% survival but failed to prevent severe clinical signs or reduce tissue viral titers, whereas low-dose molnupiravir showed outcomes comparable to placebo. These findings demonstrate the high pathogenicity of a human A(H5N1) isolate in immunosuppressed hamsters, support baloxavir as an effective therapeutic option, and identify molnupiravir-based regimens as promising strategies for severe influenza A(H5N1) infection.

Source: PLoS Pathogens, https://doi.org/10.1371/journal.ppat.1014796

____

#Maternal and perinatal #outcomes in pregnant women with #Lassa fever: analysis from the LASCOPE prospective cohort study

 

Summary

Background

Lassa fever, a viral haemorrhagic fever endemic in west Africa, is usually described as associated with severe maternal and perinatal outcomes. Previous studies reported maternal mortality of 33% (whereas overall mortality is about 14% in Nigeria for patients admitted to hospital) and fetal mortality is up to 60%. However, most evidence derives from small case series with substantial limitations. We aimed to assess maternal death and perinatal outcomes in a prospective cohort study with standardised medical care protocols.

Methods

We analysed data from the LASCOPE cohort from the Federal Medical Centre Owo, Nigeria, which included all patients with PCR-confirmed Lassa fever. In this analysis, non-pregnant women of childbearing age (15–45 years) were compared with pregnant women, defined as having an ongoing pregnancy during Lassa fever. The primary maternal outcome was all-cause mortality 28 days after admission and the primary pregnancy outcome was fetal death. Mortality at 28 days was compared using Kaplan–Meier estimates and a Cox proportional-hazards model, the cumulative incidence of fetal death was estimated with livebirth as a competing event, and the association between gestational age at symptom onset and fetal death was assessed by logistic regression.

Findings

Between April 4, 2018, and Feb 18, 2023, of 1006 patients in the LASCOPE cohort admitted with PCR-confirmed Lassa fever, 703 were excluded for not being of childbearing age, and 303 were women of childbearing age, of whom 45 were pregnant. The median age of pregnant women was 28 years (IQR 24–32). The 28-day mortality was comparable between pregnant and non-pregnant women (four [9%; 95% CI 2–21] of 45 vs 19 [7%; 95% CI 4–11] of 258; hazard ratio 1·19 [95% CI 0·41–3·50]; log-rank p=0·75). Fetal case-fatality rate was 60% (27 of 45), with higher risk of fetal death if infection occurred early in the pregnancy (100% for the first trimester, 82% for the second trimester, and 25% for the third trimester). Each additional week of gestation at symptom onset was associated with a reduction in the odds of fetal death (odds ratio 0·77 [95% CI 0·61–0·90]). Among 15 liveborn infants, three (20%) died within 30 days.

Interpretation

Although the fetal prognosis was poor, as previously reported, maternal fatality was lower than previously indicated, potentially reflecting improved supportive care and patient monitoring. These findings suggest that maternal mortality might be lower than historically reported, while confirming the urgent need for specific therapeutic interventions to improve fetal outcomes.

Funding

INSERM/REACTing; the African Coalition for Epidemic Research, Response and Training consortium; the University of Oxford; the UK Department for International Development; the Wellcome Trust; the French Ministry of Foreign Affairs; the Agence Nationale de Recherches sur le SIDA et les hépatites virales; and the French National Research Institute for Sustainable Development.

Source: The Lancet Infectious Diseases, https://doi.org/10.1016/S1473-3099(26)00524-4

____

#Transmission #dynamics of #Nipah virus in #Bangladesh and India, 2001–2026: Systematic review and inference on reproduction number, offspring dispersion, and serial interval

 

Abstract

Background

Nipah virus (NiV) is a priority zoonotic pathogen causing high-fatality outbreaks. Early NiV outbreaks in Malaysia and Singapore had limited transmission beyond spillover events. However, since 2001, NiV outbreaks with person-to-person transmission have occurred in Bangladesh and India, driven by the NiV-Bangladesh genotype and NiV-India genotype. Our study aims to estimate the reproduction number, offspring dispersion, and serial interval governing NiV transmission in Bangladesh and India during 2001–2026.

Methods

We conducted a systematic review of NiV outbreak investigations in Bangladesh and India, searching PubMed, Embase, Web of Science, and grey literature through 28 February 2026. Case-level offspring counts from 27 sources (323 cases across 67 outbreaks) were used as input to a hierarchical Bayesian negative binomial offspring distribution model. The serial interval was estimated by parametric distribution fitting to 137 transmission pairs. We conducted country-specific analysis and performed sensitivity analyses to evaluate the robustness of estimates.

Results

Pooling across 67 outbreaks, we estimated a median reproduction number of 0.43 (95% CrI: 0.26–0.75), an offspring dispersion parameter of 0.04 (0.03–0.06), and a serial interval of 13.3 days (95% CI: 12.8–13.8). Country-specific median reproduction numbers were 0.47 (0.22–0.98) for India and 0.35 (0.19–0.63) for Bangladesh, and dispersion parameters were 0.03 (0.02–0.06) and 0.05 (0.03–0.09), respectively, indicating marked overdispersion in both settings.

Conclusion

NiV transmission is self-limiting on average and highly overdispersed, suggesting that a disproportionate share of onward transmission arises from a small number of cases. This epidemiological profile supports targeted containment measures, including contact tracing and quarantine, for effective NiV outbreak control.

Source: Plos Neglected Tropical Diseases, https://doi.org/10.1371/journal.pntd.0014876

____

Cross #Protection against #Influenza #H5 Clade 2.3.4.4b Viruses after #H1N1pdm09 Infection

 

Abstract

We challenged ferrets previously infected with influenza A(H1N1)pdm09 virus with H5N1 or H5N5 clade 2.3.4.4b viruses to assess cross-protection. Results show that previous A(H1N1)pdm09 virus immunity conferred partial protection against both viruses, with slightly reduced protection against H5N5 compared with H5N1, potentially reflecting the absence of cross-reactive N5 neuraminidase antibodies.

Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.261032

____

Rare recovery of #reassortants between contemporary clade 2.3.4.4b #H5N1 viruses and #human #influenza A viruses in vitro

 

Abstract

Influenza A virus (IAV) pandemics can arise when animal-derived and human-adapted IAVs exchange genome segments; however, whether contemporary clade 2.3.4.4b H5N1 viruses can generate viable reassortants with human IAVs is unclear. Here, we tested the reassortment potential of two clade 2.3.4.4b H5N1 viruses with human-adapted H1N1 and H3N2 IAVs using a biosafe reassortment system. Across multiple coinfection conditions, we genotyped 2,698 plaque-purified viral clones and recovered 20 reassortants (0.74%). Polymerase assays identified human IAV subunits, particularly H1N1 PA or H3N2 PB2, that increased H5N1 polymerase activity. Thus, contemporary clade 2.3.4.4b H5N1 viruses can reassort with human IAVs, but factors beyond polymerase compatibility may limit their recovery.

Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2631654123

____

Broad #vaccine #protection against globally diverse #influenza #H5Nx viruses

 

Summary

Influenza A/H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide. The severity of human infections varies substantially between different H5 clades and neuraminidase (NA) reassortants, creating unpredictable pandemic risk. Existing H5 vaccines, typically based on a single hemagglutinin (HA) strain, cannot keep pace with this natural variation. To address this problem, we computationally engineer HA, NA, and M2 antigens representing the global antigenic space of circulating H5Nx viruses, prioritizing N1 and N6 subtypes associated with the highest threat in humans. The resulting digitally immune-optimized mRNA vaccine, DVX-panH5Nx, elicits broad HA neutralization and NA inhibition across divergent clades in mice and ferrets. Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.

Source: Cell Reports Medicine Journal, https://doi.org/10.1016/j.xcrm.2026.103131

____

Immunogenicity and #safety of two priming doses of an MF59-adjuvanted cell-based #H5N8 #influenza #vaccine in healthy persons aged ≥18 years

Abstract

Background

Increased transmission of avian influenza from animals to humans has elevated the risk of an H5 pandemic.

Methods

This phase 2, randomized, observer-blind, multi-center trial assessed the immunogenicity and safety of homologous priming with an MF59-adjuvanted, cell-based H5N8 A/Astrakhan/3212/2020 clade 2.3.4.4b vaccine (aH5N8c). We enrolled adults age ≥18 years, equally stratified into 18–64 (including a poultry-worker subset) and ≥65 year cohorts. Primary and secondary outcomes were homologous antibody responses against H5N8 measured in all participants by hemagglutination inhibition (HI) and in a subset by microneutralization (MN) assays on Days 1, 22, and 43. Solicited adverse events (AEs) were monitored for 7 days post-vaccination, with unsolicited AEs tracked throughout Day 43.

Results

239 participants were vaccinated (18–64 years, n = 121; ≥65 years, n = 118). At Day 43 (21 days post second aH5N8c dose), geometric mean fold increases (GMFI) were 13.7 for the 18–64 cohort and 10.2 for the ≥65 cohort. HI seroconversion rates were 75.8% (95% CI 66.1–83.8%) for the 18–64 cohort and 71.0% (61.1–79.6%) for the ≥65 cohort. HI titers ≥1:40 were achieved in 75.8% (66.1–83.8%) and 73.0% (63.2–81.4%) of participants, respectively. MN seroconversion rates were 80.6% (68.6–89.6%) and 70.0% (56.8–81.2%), while MN titers ≥1:40 were 83.9% (72.3–92.0%) and 86.7% (75.4–94.1%), respectively. No notable differences in immune responses by poultry worker status were observed. Most solicited AEs were mild or moderate, resolving within 3 days. Unsolicited AEs were reported by 16.7% participants by Day 43.

Conclusion

These data support the use of the MF59-adjuvanted, cell-based monovalent H5N8 vaccine as a public health intervention against H5 influenza.

Source: Vaccine Journal, https://doi.org/10.1016/j.vaccine.2026.129279

____

#Antigenic #landscape of a highly mutated #SARS-CoV-2 #spike in ongoing viral #evolution

 

Abstract

The ongoing emergence of SARS-CoV-2 variants in an increasingly immune-experienced population is largely enabled by the plasticity of the Spike protein, which lies at the frontline of host immune pressure. Here, we investigated how extensive remodeling of the N-terminal domain (NTD) in Spike influences its antigenic properties. Using BA.2.87.1, a variant heavily mutated in this domain, we found that even large deletions do not substantially disrupt overall Spike structure or pseudovirus infectivity. However, our structural and binding analyses revealed that the NTD exhibits increased flexibility and that interaction with a heme–metabolite, known to facilitate the exposure of an immunodominant epitope, is lost. These conformational effects, coupled with 33 NTD mutations, compromised the ability of human convalescent antibodies to engage this domain, contributing to their reduced neutralizing capacity. Consequently, BA.2.87.1-like variants may escape recognition by the preexisting NTD-targeting antibodies, potentially reducing protection. Together, our results highlight the intrinsic adaptability of the Spike beyond the receptor-binding domain, with implications for immune escape during viral evolution.

Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2608185123

____

Structure of #influenza D virus #NS1 reveals a novel Zn-binding site and ssRNA-binding activity

 

Abstract

Influenza D virus (IDV) is an emerging pathogen associated with bovine respiratory disease and has potential for zoonotic transmission. Although nonstructural protein 1 (NS1) is a major virulence factor in influenza A and B viruses, the structure and function of IDV NS1 remain poorly defined. Here, we determined crystal structures of the IDV NS1 N-terminal RNA-binding domain (NTD) and C-terminal effector domain (CTD). The NTD retains the conserved homodimeric six-helix fold, whereas the CTD adopts a distinct architecture containing a novel Zn²⁺-binding site. IDV NS1 CTD preferentially binds single-stranded RNA, and mutagenesis identified lysine and arginine residues critical for this activity. Single-residue substitutions disrupting either the Zn²⁺-binding site or RNA-binding interface prevented recovery of infectious recombinant IDV. These findings reveal distinct structural and functional features of IDV NS1 and establish the importance of CTD integrity for viral replication. Conservation of key CTD residues in influenza C virus NS1 suggests shared structural features that distinguish influenza C and D virus NS1 proteins from their influenza A and B counterparts.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Welch Foundation, https://ror.org/00np6vq88, C-1565

Source: BioRxIV, https://doi.org/10.64898/2026.10.29.760789

____

A single–amino acid difference between #rodent and #human #Andes virus affects viral #glycoprotein trafficking

 

Abstract

Andes virus (ANDV) causes hantavirus pulmonary syndrome (HPS), with rare outbreaks involving person-to-person transmission. A human ANDV isolate from one such outbreak and a rodent isolate from the same region differ in lethality in Syrian golden hamsters. Genomic analysis revealed 25 nonsynonymous substitutions, including one leading to a T641I change in the human ANDV glycoprotein precursor near its cleavage site. Although the isolates differed in growth kinetics, strand-specific RT-qPCR did not support major differences in viral RNA synthesis, whereas virion release was delayed in the case of the human isolate. In human cell expression systems, a single I641T substitution in the human ANDV glycoprotein resulted in decreased Golgi retention and faster release of virion-like particles relative to wild-type glycoprotein. Since ANDV egress takes place at the Golgi, the T641I change present in the human ANDV isolate may represent a human adaptive mutation influencing glycoprotein trafficking and virus particle release.

Source: Science Advances Journal, https://doi.org/10.1126/sciadv.aek2522

____

#Coronavirus Disease Research #References (AMEDEO, Nov. 7 '26)

 

Ann Intern Med

1. REEDER HT, Donohue SE, Martin JN, Hornig M, et al
   Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants.
   Ann Intern Med. 2026 Nov 3. doi: 10.7326/ANNALS-25-05275.
   PubMed         Abstract available
   
   

   
   Antiviral Res

2. LU Y, Yang S, Hou M, Yu L, et al
   4-octyl itaconate inhibits porcine epidemic diarrhea virus replication by modulating the ferroptosis axis and the autophagy pathway.
   Antiviral Res. 2026;255:106535.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. LU M, Qiao M, Chen S, Zhu J, et al
   Human metapneumovirus-associated ARI hospitalisation rates in comparison to respiratory syncytial virus and influenza in eastern China, 2020-2024: a time-series analysis.
   Int J Infect Dis. 2026 Nov 5:109235. doi: 10.1016/j.ijid.2026.109235.
   PubMed         Abstract available
   
   
4. COLOSI E, Calmon L, Fassli M, Koch KN, et al
   Pooled testing for SARS-CoV-2 surveillance in schools: evaluation of transmission control, testing resources, and educational disruption.
   Int J Infect Dis. 2026 Nov 4:109233. doi: 10.1016/j.ijid.2026.109233.
   PubMed         Abstract available
   
   
5. KOK J, Bott L, Wiid Z, Williamson A, et al
   The Impact of Socioeconomic and Geographic Factors in Respiratory Virus Testing in Australia.
   Int J Infect Dis. 2026 Oct 31:109210. doi: 10.1016/j.ijid.2026.109210.
   PubMed         Abstract available
   
   

   
   J Med Virol

6. ZETUM ASS, Silva DRCD, Ventorim VDP, Mion FA, et al
   Deciphering Host Genomic Pathway Landscapes in Severe COVID-19 by Exome Sequencing of a Large Admixed Brazilian Cohort.
   J Med Virol. 2026;98:e71193.
   PubMed         Abstract available
   
   

   
   J Virol

7. BIRD B, Thorn L, Aminisani N, Wood T, et al
   Incidence and risk factors of acute respiratory illness associated with influenza, COVID-19, and respiratory syncytial virus within a birth cohort study.
   J Virol. 2026 Nov 6:e0086326. doi: 10.1128/jvi.00863.
   PubMed         Abstract available
   
   
8. FRIEMAN MB, Menachery VD
   Outstanding scientific talent devoted to consequential problems.
   J Virol. 2026 Nov 5:e0145126. doi: 10.1128/jvi.01451.
   PubMed         Abstract available
   
   
9. LACASSE E, Dubuc I, Leclerc J, Gravel A, et al
   SARS-CoV-2 Nsp2 reprograms host immunity to drive pathogenic inflammation.
   J Virol. 2026 Nov 5:e0133326. doi: 10.1128/jvi.01333.
   PubMed         Abstract available
   
   
10. ZHANG Y, Bai B, Tang Y, Wang C, et al
    PEDV NSP5 promotes immune evasion by recruiting TRIM28 to degrade DDX3X.
    J Virol. 2026 Nov 4:e0151026. doi: 10.1128/jvi.01510.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

11. HAPPLE C, Hoffmann M, Stankov MV, Chen N, et al
    Humoral immunity after mRNA SARS-CoV-2 XFG vaccination.
    Lancet Infect Dis. 2026 Nov 5:S1473-3099(26)00569.
    PubMed        
    
    

    
    Nature

12. FIELDHOUSE R
    The surprising reason women in academia do more parenting than men.
    Nature. 2026 Nov 5. doi: 10.1038/d41586-026-03568.
    PubMed        
    
    

    
    Science

13. HANSEN CH, Lipstein M, Erlandson SC, Schwalbe T, et al
    Discovering molecular modulators with nanoswitch screening.
    Science. 2026;394:eadt7185.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Nov. 7 '26)

 

Antiviral Res

1. NAGAHAWATTA DP, Jeong SH, Liyanage NM, Jayawardena TU, et al
   Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
   Antiviral Res. 2026 Sep 15:106532. doi: 10.1016/j.antiviral.2026.106532.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. DANILENKO AV, Svyatchenko SV, Bragina MK, Goncharova NI, et al
   Characterization of influenza A(H3N2) viruses detected on a pig farm in Russia in 2017-2018.
   Arch Virol. 2026;171:314.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

3. ESTEVES L, Raymundo CE, de Andrade Medronho R
   Associated factors for COVID-19 mortality among children and adolescents in Rio de Janeiro state, 2020-2023.
   BMC Pediatr. 2026;26:1087.
   PubMed         Abstract available
   
   
4. CHEN T, Guo X, Tang W, Liu F, et al
   Clinical characteristics and risk factors for poor prognosis of RSV lower respiratory tract infection: a two-center study.
   BMC Pediatr. 2026;26:1085.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

5. LAU JY, Pan WC, Ji DD
   Transmission-route-specific trends in communicable diseases in Taiwan: an interrupted time-series analysis.
   Epidemiol Infect. 2026;154:e146.
   PubMed         Abstract available
   
   

   
   J Exp Med

6. SUN R, Lin S, Simonelli L, Strunz B, et al
   Cellular origin and characterization of autoantibodies against type I IFNs in COVID-19 and APS-1.
   J Exp Med. 2026;223:e20260268.
   PubMed         Abstract available
   
   

   
   J Infect Dis

7. MEEKER JR, Price AM, Martin E, Vaughn I, et al
   Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016-17 Through 2024-25.
   J Infect Dis. 2026 Oct 31:jiag538. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Neurosurg Pediatr

8. ROBERTS CR, Jin R, Parker M, Spader HS, et al
   A decade of change in pediatric intracranial abscess surgery: rising volumes and evolving care (2013-2023).
   J Neurosurg Pediatr. 2026;38:642-648.
   PubMed         Abstract available
   
   

   
   J Virol

9. BIRD B, Thorn L, Aminisani N, Wood T, et al
   Incidence and risk factors of acute respiratory illness associated with influenza, COVID-19, and respiratory syncytial virus within a birth cohort study.
   J Virol. 2026 Nov 6:e0086326. doi: 10.1128/jvi.00863.
   PubMed         Abstract available
   
   

   
   Pediatrics

10. 
    Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Policy Statement.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079045.
    PubMed         Abstract available
    
    
11. 
    Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079049.
    PubMed         Abstract available
    
    
12. 
    Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Technical Report.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079046.
    PubMed         Abstract available
    
    
13. 
    Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement.
    Pediatrics. 2026 Sep 2. doi: 10.1542/peds.2026-079047.
    PubMed         Abstract available
    
    
14. ESTEBAN RIERA I, Perez-Caballero R, Natalini Martinez S, Gonzalez-Amores M, et al
    Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents.
    Pediatrics. 2026 Oct 23:e2026076225. doi: 10.1542/peds.2026-076225.
    PubMed         Abstract available
    
    
15. HIGGINS DM, Gurfinkel D, Dorsey B, O'Leary ST, et al
    Frontline Staff Vaccine Communication During Pediatric Well-Child Encounters: A Mixed-Methods Study.
    Pediatrics. 2026 Oct 23:e2026077450. doi: 10.1542/peds.2026-077450.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. LEBATTEUX D, Corso F, Soudeyns H, Boucoiran I, et al
    KmerSignificance score: A discriminative and biologically informed framework for viral k-mer prioritization.
    PLoS Comput Biol. 2026;22:e1014332.
    PubMed         Abstract available
    
    

    
    PLoS Med

17. BENJAMIN H, Barnsley G, Watson OJ, Jit M, et al
    Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation.
    PLoS Med. 2026;23:e1004772.
    PubMed         Abstract available
    
    
18. GAVISH N, Huppert A
    Transforming pandemic influenza antiviral stockpiling using a capacity-based approach: A modeling study.
    PLoS Med. 2026;23:e1004992.
    PubMed         Abstract available
    
    

    
    PLoS One

19. WANG S, Xia Z, Shi B, Chen M, et al
    Weekly dynamics, subtype replacement and regional heterogeneity of influenza activity in China, 2024-2026: A national sentinel surveillance analysis.
    PLoS One. 2026;21:e0361588.
    PubMed         Abstract available
    
    
20. ALKADI MM, Abuhelaiqa EA, Abdul Rahman RM, Mahgoub AB, et al
    Assessment of coronavirus disease 2019 mRNA vaccine response in kidney transplant recipients.
    PLoS One. 2026;21:e0359640.
    PubMed         Abstract available
    
    
21. SVENSSON A, Sonnerfors P, Holmstrom L, Nygren-Bonnier M, et al
    Experiences of individually tailored physical exercise in COVID-19-induced postural orthostatic tachycardia syndrome: A qualitative content analysis.
    PLoS One. 2026;21:e0360748.
    PubMed         Abstract available
    
    
22. ZHAO X, Deng L, Ford ND, Saydah S, et al
    Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity.
    PLoS One. 2026;21:e0345433.
    PubMed         Abstract available
    
    
23. CANIZALES GALAVIZ J, Khan A, Tourki B, Patarroyo-White S, et al
    eNAMPT is a plasma biomarker of COVID-19 severity and ARDS progression linked to increased immune effector cell expression.
    PLoS One. 2026;21:e0360244.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. SCHOWE AM, Ruks M, Disselkamp CKL, Kuznetsov DV, et al
    Epigenetic aging during the COVID-19 pandemic: A prospective longitudinal study with prepandemic baseline data in children, adolescents, and adults.
    Proc Natl Acad Sci U S A. 2026;123:e2604211123.
    PubMed         Abstract available
    
    
25. CHARLESWORTH TES, Doyle MC, Banaji MR
    Patterns of implicit and explicit attitudes V: Increases in bias from 2021 to 2025.
    Proc Natl Acad Sci U S A. 2026;123:e2619420123.
    PubMed         Abstract available
    
    
26. ZAPF AJ, Dewey G, Ognyanova K, Baum MA, et al
    Trust as a hidden driver of epidemic-relevant behavior: Institution- and behavior-specific associations across 20 national survey waves.
    Proc Natl Acad Sci U S A. 2026;123:e2622260123.
    PubMed         Abstract available
    
    

    
    Vaccine

27. TRAN S, McClymont E, Blitz S, Barrett J, et al
    Erratum to "Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada" [Vaccine 92 (2026) 129122].
    Vaccine. 2026 Oct 31:129306. doi: 10.1016/j.vaccine.2026.129306.
    PubMed        
    
    

    
    Virology

28. DUDIN GA, Alkubaisi NA, Aziz IM, Ikram A, et al
    The role of cytokines as immunological biomarkers of disease severity during respiratory syncytial virus (RSV) infection in children.
    Virology. 2027;625:111102.
    PubMed         Abstract available

#Hantavirus #Outbreak Caused by #Andes Virus Linked to International Cruise #Ship #Travel — #USA, 2026

 

Abstract

Andes virus (ANDV), the only hantavirus known to be transmitted person-to-person, is endemic to areas of South America and can cause hantavirus pulmonary syndrome, which has a case-fatality rate of approximately 40%. On May 4, 2026, CDC was notified of seven cases of severe acute respiratory illness, including three deaths, among 147 persons aboard a cruise ship in the Atlantic Ocean; the illnesses were later confirmed to be caused by ANDV. No cases occurred among passengers who were U.S. residents. Ten of 28 U.S. resident passengers disembarked before ANDV infection was confirmed aboard the ship. On May 10, the remaining 18 U.S. resident passengers were repatriated to the National Quarantine Unit in Omaha, Nebraska, for risk assessment and monitoring, and where optimized advanced care was available, should symptoms develop. CDC and U.S. health departments monitored 60 additional U.S. residents potentially exposed on flights involving a passenger with symptomatic ANDV infection from the cruise, totaling 88 contacts across 27 jurisdictions. All 88 contacts completed 42 days of monitoring, with no secondary ANDV infections identified. Worldwide, local health authorities assessed and monitored approximately 653 potentially exposed persons from 33 countries. This response highlights the value of rapid coordination among partners to locate and monitor potentially exposed persons during an international outbreak to reduce the risk for ANDV transmission. Prompt notification to public health authorities can facilitate testing, patient care, contact identification, and implementation of measures to limit secondary transmission.

Source: Morbidity and Mortality Weekly Report, http://dx.doi.org/10.15585/mmwr.mm7543a1

____

#Andes virus on cruise #ships: An #evidence-stratified #review of #transmission risks and #biosecurity strategies

 

Abstract

The 2026 Andes virus (ANDV) cluster associated with the merchant vessel (MV) Hondius cruise ship highlights the limitations of hantavirus control strategies that have traditionally focused on rodent-source exposure alone. No evidence supports heating, ventilation, and air conditioning (HVAC)-mediated long-distance ANDV spread. Such strategies are insufficient for ecologically sensitive cruise routes, enclosed ocean-going environments, international passenger movement, and limited onboard medical capacity. Current evidence indicates that ANDV has limited but documented potential for person-to-person transmission. Transmission is most plausibly associated with acute-phase viremia, exposure to body fluids or short-range droplets, prolonged close contact, caregiving, and specific contextual conditions; it should not be equated with sustained community transmission by highly efficient respiratory viruses. On the basis of epidemiologic investigations, clinical shedding studies, animal models, viral genetic evidence, and environmental stability data, this review analyzes how high-consequence pathogens may have their public health impact amplified in cruise-ship settings. It further proposes prevention and control measures covering pre-voyage ecological exposure assessment, embarkation screening, early onboard recognition, tiered isolation, rapid shipboard testing, medical evacuation, and cross-border coordination. The central lesson from the MV Hondius event is that cruise ships operating on ecologically sensitive routes should move beyond conventional sanitation-centered management toward a whole-of-journey biosecurity model based on evidence stratification and graded response.

Source: Biosafety and Health Journal, https://doi.org/10.1016/j.bsheal.2026.07.006

____

#Serologic Evidence of Avian #Influenza Virus Exposure in #Livestock, #Egypt, 2024–2026

 

Abstract

Spillover of influenza A(H5N1) virus to cattle in the United States sparked global concern. We investigated whether endemic avian influenza viruses are potentially spilling over into domestic livestock in Egypt. We detected influenza H9N2 antibodies in 2.5% and H5N1 antibodies in 2.9%–4.5% of tested animals. Additional surveillance will elucidate host infection dynamics.

Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260869

____

#Fatal Disseminated #Powassan Virus #Infection in #Transplant Recipient, #Pennsylvania, #USA

 

Abstract

We describe histopathologic findings from a fatal case of Powassan virus lineage 2 (deer tick virus) in an immunosuppressed liver transplant patient in Pennsylvania, USA. We confirmed infection in postmortem brain, lung, and kidney by immunohistochemistry, in situ hybridization, and reverse transcription PCR, demonstrating infection of pulmonary and renal tissues.

Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260193

____

#Pathogenicity and #zoonotic potential of a novel pdm09-lineage #H1N2 swine #influenza A virus spatiotemporally linked to transboundary #pig trade

 

Abstract

International swine trade can disseminate influenza A viruses across borders, creating opportunities for reassortment with endemic swine viruses and the emergence of novel strains with zoonotic potential. Here, we characterize a novel H1N2 reassortant, A/swine/Korea/1030–3/2023 (1030–3), detected in South Korea and spatiotemporally associated with European swine lineages and international pig movement. 1030–3 harbors seven gene segments (PB2, PB1, PA, HA, NP, M and NS) closely related to a recent Danish zoonotic H1N1 virus of the 2009 pandemic (pdm09) lineage, and an N2 segment derived from an endemic Korean HxN2. In vitro assays demonstrated that 1030–3 preferentially bound human-type α2,6-linked sialic acid receptors and replicated efficiently in polarized human airway epithelial cells, although these properties were also observed in the endemic Korean H1N2 comparator 1027–1. In mice, 1030–3 caused moderate clinical signs and respiratory replication comparable to an early pdm09 reference strain NL09. In guinea pigs, 1030–3 transmitted to a subset of direct-contact animals but showed no detectable aerosol transmission under the conditions tested. In pigs, the natural host, 1030–3 replicated efficiently and transmitted to all direct-contact animals, with high respiratory shedding and a greater cumulative shedding burden in contact pigs than NL09. Contemporary human sera showed reduced neutralizing activity against 1030–3 relative to both human seasonal H1N1 and 1027–1, while antiserum against a recent H1N1 vaccine antigen also neutralized 1030–3 less efficiently. These findings identify a European-associated H1N2 swine influenza reassortant detected in South Korea that combines a distinct pdm09-derived genomic and antigenic background with efficient replication and transmission in pigs, α2,6-linked receptor preference, and reduced neutralization by human sera, underscoring the need for trade-aware surveillance of swIAVs and continued monitoring at the swine-human interface.

Source: PLoS Pathogens, https://doi.org/10.1371/journal.ppat.1014779

____

#Zoonotic Exposure to Porcine #Deltacoronavirus, #USA, 2019–2021

 

Abstract

Porcine deltacoronavirus (PDCoV) is a swine coronavirus with zoonotic potential. We detected PDCoV-neutralizing antibodies in 10 of 300 human serum samples; positive sample sources included 1 adult and 9 juveniles. Our findings provide evidence of human exposure to PDCoV and highlight the importance of monitoring animal coronaviruses with zoonotic potential.

Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260303

____